Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Fineline Cube May 19, 2026
Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026
Company Drug

CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials

Fineline Cube Sep 15, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small‑molecule, SYH2066, has been...

Company Drug

Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis

Fineline Cube Sep 15, 2025

China‑based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection...

Company Deals

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor

Fineline Cube Sep 15, 2025

China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...

Drug

Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B

Fineline Cube Sep 15, 2025

In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA)...

Company Drug

Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS

Fineline Cube Sep 15, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody‑drug conjugate...

Company Deals Medical Device

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Fineline Cube Sep 15, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...

Company Deals

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

Fineline Cube Sep 15, 2025

China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...

Company Deals

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth

Fineline Cube Sep 15, 2025

A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...

Policy / Regulatory

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications

Fineline Cube Sep 15, 2025

The National Medical Products Administration (NMPA) has just published the 96th edition of its Reference...

Company Drug

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer

Fineline Cube Sep 12, 2025

CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...

Company Drug

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Fineline Cube Sep 12, 2025

BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...

Company Drug

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference

Fineline Cube Sep 12, 2025

Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...

Company

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

Fineline Cube Sep 12, 2025

Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...

Company Policy / Regulatory

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

Fineline Cube Sep 12, 2025

The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...

Company

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US

Fineline Cube Sep 12, 2025

US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...

Company Drug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration

Fineline Cube Sep 12, 2025

Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...

Drug Policy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Fineline Cube Sep 12, 2025

The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...

Company Drug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

Fineline Cube Sep 11, 2025

China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Deals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Fineline Cube Sep 11, 2025

China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...

Company Deals Drug

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

Fineline Cube Sep 11, 2025

Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...

Posts pagination

1 … 105 106 107 … 668

Recent updates

  • Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
  • Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
  • Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
  • Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.